Skip to main content


1. de Vrese M, Schrezenmeir J.: Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol.
2. Oguz Resat Sipahi.: Economics of Antibiotic Resistance Expert Rev Anti Infect Ther. 2008;6(4):523-539.
3. Steed H, Macfarlane GT, Macfarlane S.: Prebiotics, synbiotics and inflammatory bowel disease. Mol
Nutr Food Res 2008 Aug;52(8):898-905.
4. Laukoetter MG, Nava P, Nusrat A.: Role of the intestinal barrier in inflammatory bowel disease. World
J Gastroenterol. 2008 Jan 21;14(3):401-7.
5. Fedorak RN.: Understanding why probiotic therapies can be effective in treating IBD. J Clin Gastroenterol
2008 Sep;42 Suppl 3 Pt 1:S111-5.
6. Vanderpool C, Yan F, Polk DB.: Mechanisms of probiotic action: Implications for therapeutic applications
in inflammatory bowel diseases. Inflamm Bowel Dis. 2008 Nov;14(11):1585-96.
7. Oliver Brain; Simon P.L.: Travis Therapy of Ulcerative Colitis: State of the Art. Curr Opin Gastroenterol.
8. A. K. Akobeng Review Article: The Evidence Base for Interventions Used to Maintain Remission in
Crohn’s Disease. Aliment Pharmacol Ther. 2008;27(1):11-18.
9. Schultz M, Lindström AL.: Rationale for probiotic treatment strategies in inflammatory bowel disease.
Expert Rev Gastroenterol Hepatol. 2008 Jun;2(3):337-55.
10. M.A Kamm Review Article: New Drug Formulations, Chemical Entities and Therapeutic Approaches
for the Management of Ulcerative Colitis. Aliment Pharmacol Ther. 2008;28(7):815-829.
11. Lee JH, Lee B, Lee HS, Bae EA, Lee H, Ahn YT, Lim KS, Huh CS, Kim DH.: Lactobacillus suntoryeus
inhibits pro-inflammatory cytokine expression and TLR-4-linked NF-kappaB activation in experimental
colitis. Int J Colorectal Dis. 2008 Dec 3. [Epub ahead of print] 12. Barbara G, Stanghellini V, Cremon C, De Giorgio R, Gargano L, Cogliandro R, Pallotti F, Corinaldesi R.:
Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use. J Clin Gastroenterol.
2008 Sep;42 Suppl 3 Pt 2:S214-7.
13. Wilhelm SM, Brubaker CM, Varcak EA, Kale-Pradhan PB.: Effectiveness of Probiotics in the Treatment
of Irritable Bowel Syndrome. Pharmacotherapy. 2008;28(4):496-505.
Gastro 2009.qxd 5/9/2009 1:42 PM Page 435
436 Gastro Update 2009
14. Spiller R.: Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol
Ther. 2008 Aug 15;28(4):385-96.
15. McFarland LV, Dublin S.: Meta-analysis of probiotics for the treatment of irritable bowel syndrome.
World J Gastroenterol. 2008 May 7;14(17):2650-61.
16. Zeng J, Li YQ, Zuo XL, Zhen YB, Yang J, Liu CH.: Effect of Active Lactic Acid Bacteria on Mucosal
Barrier Function in Patients With Diarrhoea-Predominant Irritable Bowel Syndrome. Aliment Pharmacol
Ther. 2008;28(8):994-1002.
17. Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P.: A double blind
randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
Gastroenterol Clin Biol 2008 Feb;32(2):147-52.
18. Williams E, Stimpson J, Wang D, Plummer S, Garaiova I, Barker M, Corfe B.: Clinical trial: a multistrain
probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind
placebo-controlled study. Aliment Pharmacol Ther. 2008 Sep 10. [Epub ahead of print] 19. Kajander K, Myllyluoma E, Rajiliæ-Stojanoviæ M, Kyrönpalo S, Rasmussen M, Jûrvenpûû S, Zoetendal
EG, de Vos WM, Vapaatalo H, Korpela R.: Clinical trial: multispecies probiotic supplementation
alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment
Pharmacol Ther. 2008;27(1):48-57.
20. Halsey J.: Current and future treatment modalities for Clostridium difficile-associated disease. Am J
Health Syst Pharm. 2008 Apr 15;65(8):705-15.
21. Doron SI, Hibberd PL, Gorbach SL.: Probiotics for prevention of antibiotic-associated diarrhea. J Clin
Gastroenterol. 2008 Jul;42 Suppl 2:S58-63.
22. Pillai A, Nelson R.: Probiotics for treatment of Clostridium difficile-associated colitis in adults.
Cochrane Database Syst Rev. 2008 Jan 23;(1):CD004611.
23. Koning CJ, Jonkers DM, Stobberingh EE, Mulder L, Rombouts FM, Stockbrügger RW.: The effect of a
multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking
the antibiotic amoxycillin. Am J Gastroenterol 2008;103(1):178-89.
24. Ruszczyòski M, Radzikowski A, Szajewska H.: Clinical trial: effectiveness of Lactobacillus rhamnosus
(strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Aliment
Pharmacol Ther. 2008 Jul;28(1):154-61.
25. Demeter P.:A probiotikumok alkalmazásának lehetõségei emésztõszervi betegségekben. LAM 2006;16(1):41-47.
26. Bhatia SJ, Kochar N, Abraham P, Nair NG, Mehta AP.: Lactobacillus acidophilus inhibits growth of
Campylobacter pylori in vitro. J Clin Microbiol 1989;27:2328-30.
27. Lorca GL, Wadstrom T, Valdez GF, Ljungh A.: Lactobacillus acidophilus autolysins inhibit Helicobacter
pylori in vitro. Curr Microbiol 2001;42:39-44.
28. Canducci F, Armuzzi A, Cremonini F, Cammarota G, Bartolozzi F et al.: A lyophilized and inactivated
culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol
Ther 2000;14:1625-9.
29. Saad RJ, Chey WD.: Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy –
What’s Next? Clin Gastroenterol Hepatol. 2008;6(10):1086-1090.
30. Graham DY, Shiotani A.: New Concepts of Resistance in the Treatment of Helicobacter pylori Infections.
Nat Clin Pract Gastroenterol Hepatol. 2008;5(6):321.
31. Zhang L, Su P, Henriksson A, O’Rourke J, Mitchell H.: Investigation of the immunomodulatory effects
of Lactobacillus casei and Bifidobacterium lactis on Helicobacter pylori infection. Helicobacter. 2008
Gastro 2009.qxd 5/9/2009 1:42 PM Page 436
Gyógyszerek, therápia 437
32. Myllyluoma E, Ahonen AM, Korpela R, Vapaatalo H, Kankuri E.: Effects of multispecies probiotic
combination on helicobacter pylori infection in vitro. Clin Vaccine Immunol. 2008 Sep;15(9):1472-82.
33. Imase K, Takahashi M, Tanaka A, Tokunaga K, Sugano H, Tanaka M, Ishida H, Kamiya S, Takahashi S.:
Efficacy of Clostridium butyricum preparation concomitantly with Helicobacter pylori eradication therapy
in relation to changes in the intestinal microbiota. Microbiol Immunol. 2008 Mar;52(3):156-61.
34. Francavilla R, Lionetti E, Castellaneta SP, Magista AM, Maurogiovanni G, Bucci N, De Canio A,
Indrio F, Cavallo L, Ierardi E, Miniello VL.: Inhibition of Helicobacter pylori infection in humans by
Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter. 2008
35. Kim MN, Kim N, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Kim JS, Jung HC, Song IS.:
The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter. 2008
36. Scaccianoce G, Zullo A, Hassan C, Gentili F, Cristofari F, Cardinale V, Gigliotti F, Piglionica D, Morini S.:
Triple therapies plus different probiotics for Helicobacter pylori eradication. Eur Rev Med Pharmacol
Sci. 2008;12(4):251-6.
37. Solga SF.: Probiotics can treat hepatic encephalopathy. Medical Hypotheses 2003;61:307-13.
38. O’Sullivan DJ.: Genomics can advance the potential for probiotic cultures to improve liver and overall
health. Curr Pharm Des. 2008;14(14):1376-81.
39. Purohit V, Bode JC, Bode C, Brenner DA, Choudhry MA, Hamilton F, Kang YJ, Keshavarzian A, Rao R,
Sartor RB, Swanson C, Turner JR.: Alcohol, intestinal bacterial growth, intestinal permeability to
endotoxin, and medical consequences: summary of a symposium. Alcohol. 2008 Aug;42(5):349-61.
40. Jasmohan S Bajaj: Management Options for Minimal Hepatic Encephalopathy. Expert Rev Gastroenterol Hepatol.
41. Bajaj JS, Saeian K, Christensen KM, Hafeezullah M, Varma RR, Franco J, Pleuss JA, Krakower G,
Hoffmann RG, Binion DG.: Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J
Gastroenterol. 2008 Jul;103(7):1707-15.
42. Nicaise C, Prozzi D, Viaene E, Moreno C, Gustot T, Quertinmont E, Demetter P, Suain V, Goffin P,
Deviere J, Hols P.: Control of acute, chronic, and constitutive hyperammonemia by wild-type and
genetically engineered Lactobacillus plantarum in rodents. Hepatology. 2008 Oct;48(4):1184-92.
43. Vleggaar FP, Monkelbaan JF, van Erpecum KJ.: Probiotics in primary sclerosing cholangitis: a
randomized placebo-controlled crossover pilot study. Eur J Gastroenterol Hepatol. 2008 Jul;20(7):688-92.
44. Lazo M, Clark JM.: The Epidemiology of Nonalcoholic Fatty Liver Disease: A Global Perspective.
Semin Liver Dis. 2008;28(4):339-350.
45. Oh MK, Winn J, Poordad F.: Review Article: Diagnosis and Treatment of Non-alcoholic Fatty Liver
Disease. Aliment Pharmacol Ther. 2008;28(5):503-522.
46. Guerrero Hernández I, Torre Delgadillo A, Vargas Vorackova F, UribM.: Intestinal flora, probiotics, and
cirrhosis. Ann Hepatol. 2008 Apr-Jun;7(2):120-4.
47. Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, Szabo G.: VSL#3 probiotic
treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic
steatohepatitis model in mice. Hepatology. 2008 Dec 29. [Epub ahead of print] 48. Stadlbauer V, Mookerjee RP, Hodges S, Wright GA, Davies NA, Jalan R.: Effect of probiotic treatment
on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis.
J Hepatol. 2008 Jun;48(6):945-51.